Idiopathic pulmonary fibrosis (IPF) is one of many rare interstitial lung diseases that exist. It has an estimated prevalence of 13 to 20 per 100,000 people worldwide. Unfortunately, there is no cure.
Dr. Naftali Kaminski, Professor at the Yale School of Medicine, is one of the researchers that has been advancing our understanding of the molecular and cellular basis of the disease. Using single cell sequencing, his laboratory has built an IPF Cell Atlas that is helping define disease-specific transcriptional profiles and functions in disease pathophysiology. With his long standing research in pulmonary fibrosis, he has collaborated with global researchers to investigate the immunopathology of COVID-19.
With insights from a professional in the field, we will learn about the current research and efforts made by healthcare professionals to revolutionize immunophenotyping in advanced lung diseases.